CIBC Asset Management
APLS

CIBC Asset Management’s Apellis Pharmaceuticals APLS Stock Holding History

CIBC Asset Management’s Portfolio APLS Stock Details APLS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q3 		– Sell
-2,612
Closed -$238K – 1052
2023
Q2 		$238K Buy
+2,612
New +$225K ﹤0.01% 881
2022
Q4 		– Sell
-3,633
Closed -$248K – 1075
2022
Q3 		$248K Buy
+3,633
New +$215K ﹤0.01% 975

Other funds holding APLS

Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
ACA
Avoro Capital Advisors New York $11.1B AUM 207.82% 1-Year Est. Return
EC
EcoR1 Capital San Francisco, California $2.06B AUM 215.32% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
T. Rowe Price Investment Management
T. Rowe Price Investment Management Baltimore, Maryland $153B AUM 38.14% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Jennison Associates
Jennison Associates New York $167B AUM 44.17% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
OCA
Octagon Capital Advisors New York $1.11B AUM 866.76% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

CIBC Asset Management's APLS Position: Q3 2023 in Review

CIBC Asset Management sold out of Apellis Pharmaceuticals (APLS) in Q3 2023, closing a stake of 2,612 shares — an estimated $238K sold.

CIBC Asset Management first reported a position in APLS in Q3 2022 and held it in 2 quarters. The position peaked at $248K in Q3 2022. 256 funds tracked by Wall St. Rank hold APLS as of Q3 2023.

  • CIBC Asset Management reported no remaining Apellis Pharmaceuticals position as of Q3 2023 after selling out during the quarter.
  • CIBC Asset Management sold 2,612 Apellis Pharmaceuticals shares in Q3 2023, an estimated $238K.
  • CIBC Asset Management first reported a position in Apellis Pharmaceuticals in Q3 2022 and held it in 2 quarters.
  • CIBC Asset Management's Apellis Pharmaceuticals position peaked at $248K in Q3 2022.
  • 256 funds tracked by Wall St. Rank held Apellis Pharmaceuticals as of Q3 2023.

Based on CIBC Asset Management's 13F filing for Q3 2023, filed 30 Oct 2023.